These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

218 related items for PubMed ID: 12544532

  • 61. Successful treatment of cervical esophageal perforation in Behcet's disease with drainage operation and infliximab.
    Mussack T, Landauer N, Ladurner R, Schiemann U, Goetzberger M, Burchardi C, Folwaczny C, Heldwein W, Hallfeldt K.
    Am J Gastroenterol; 2003 Mar; 98(3):703-4. PubMed ID: 12650819
    [No Abstract] [Full Text] [Related]

  • 62. Successful treatment of refractory Behçet's disease with the TNF-alpha blocker infliximab.
    Jalili A, Kinaciyan T, Barisani T, Peck-Radosavljevic M, Stingl G, Geusau A, Wöhrl S.
    Iran J Immunol; 2009 Mar; 6(1):55-8. PubMed ID: 19293479
    [No Abstract] [Full Text] [Related]

  • 63. Anti-tumor necrotic factor antibody for treatment of neuro-Behçet's disease, a case report.
    Borhani Haghighi A, Safari A.
    Clin Neurol Neurosurg; 2008 Mar; 110(3):315-6. PubMed ID: 18053588
    [No Abstract] [Full Text] [Related]

  • 64. A case of Behçet's disease treated with a humanized anti-interleukin-6 receptor antibody, tocilizumab.
    Hirano T, Ohguro N, Hohki S, Hagihara K, Shima Y, Narazaki M, Ogata A, Yoshizaki K, Kumanogoh A, Kishimoto T, Tanaka T.
    Mod Rheumatol; 2012 Apr; 22(2):298-302. PubMed ID: 21748365
    [Abstract] [Full Text] [Related]

  • 65. The effectiveness of the anti-tumor necrosis factor therapy infliximab in neuro-Behçet's disease: a systematic review and meta-analysis.
    Mohammed RHA, Woldeamanuel YW.
    J Int Med Res; 2023 May; 51(5):3000605231169895. PubMed ID: 37203384
    [Abstract] [Full Text] [Related]

  • 66. An attack of acute neuro-Behçet's disease during the course of chronic progressive neuro-Behçet's disease: report of two cases.
    Matsui T, Ishida T, Tono T, Yoshida T, Sato S, Hirohata S.
    Mod Rheumatol; 2010 Dec; 20(6):621-6. PubMed ID: 20617356
    [Abstract] [Full Text] [Related]

  • 67.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 68.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 69. Tumor necrosis factor alpha antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitis.
    Baert FJ, D'Haens GR, Peeters M, Hiele MI, Schaible TF, Shealy D, Geboes K, Rutgeerts PJ.
    Gastroenterology; 1999 Jan; 116(1):22-8. PubMed ID: 9869598
    [Abstract] [Full Text] [Related]

  • 70. Regression of optic disc neovascularization in patients with Behçet's uveoretinitis after infliximab therapy.
    Kawaguchi T, Sugita S, Yamada Y, Miyanaga M, Mochizuki M.
    J Ocul Pharmacol Ther; 2010 Dec; 26(6):627-30. PubMed ID: 21043804
    [Abstract] [Full Text] [Related]

  • 71. Effect of infliximab in progressive neuro-Behçet's syndrome.
    Kikuchi H, Aramaki K, Hirohata S.
    J Neurol Sci; 2008 Sep 15; 272(1-2):99-105. PubMed ID: 18550081
    [Abstract] [Full Text] [Related]

  • 72. Laryngeal involvement in Behcet's disease--a challenge for treatment.
    Gross M, Ben-Chetrit E.
    Clin Rheumatol; 2013 Mar 15; 32 Suppl 1():S75-7. PubMed ID: 20532579
    [Abstract] [Full Text] [Related]

  • 73. Infliximab-induced thrombocytopenia in an elderly patient with ileocolonic Crohn's disease.
    Mocciaro F, Russo G, Di Mitri R, Marino A.
    Inflamm Bowel Dis; 2013 Mar 15; 19(4):E52-3. PubMed ID: 22535599
    [No Abstract] [Full Text] [Related]

  • 74. Behçet's syndrome: from aetiology to treatment.
    Powell RJ.
    Adv Exp Med Biol; 2003 Mar 15; 528():481-6. PubMed ID: 12918749
    [No Abstract] [Full Text] [Related]

  • 75. Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders.
    Levy-Clarke G, Jabs DA, Read RW, Rosenbaum JT, Vitale A, Van Gelder RN.
    Ophthalmology; 2014 Mar 15; 121(3):785-96.e3. PubMed ID: 24359625
    [Abstract] [Full Text] [Related]

  • 76. Behçet's disease: recent advances in early diagnosis and effective treatment.
    Calamia KT, Kaklamanis PG.
    Curr Rheumatol Rep; 2008 Oct 15; 10(5):349-55. PubMed ID: 18817637
    [Abstract] [Full Text] [Related]

  • 77. Ulcerative intestinal tuberculosis case as a complication of treatment by infliximab for intestinal Behçet's disease: A case report.
    Shen Y, Ma HF, Yang YL, Guan JL.
    Medicine (Baltimore); 2019 Oct 15; 98(43):e17652. PubMed ID: 31651888
    [Abstract] [Full Text] [Related]

  • 78. Long-lasting remission of severe Behçet's disease after the end of infliximab therapy.
    Olivieri I, Padula A, Leccese P, D'Angelo S, Giasi V.
    J Rheumatol; 2009 Apr 15; 36(4):855. PubMed ID: 19342728
    [No Abstract] [Full Text] [Related]

  • 79. Gastrointestinal Behçet's disease: Manifestations, diagnosis, and management.
    Manuelyan Z, Butt E, Parupudi S.
    Dis Mon; 2024 Jan 15; 70(1S):101674. PubMed ID: 38185603
    [Abstract] [Full Text] [Related]

  • 80. Infliximab for patients with neuro-Behcet's disease: case series and literature review.
    Borhani Haghighi A, Safari A, Nazarinia MA, Habibagahi Z, Shenavandeh S.
    Clin Rheumatol; 2011 Jul 15; 30(7):1007-12. PubMed ID: 21431864
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.